EGFR and non-small cell lung carcinoma: In a randomized phase 2 trial of dacomitinib versus erlotinib after one or two lines of chemotherapy for advanced NSCLC, PFS was prolonged with dacomitinib in the overall population (2.86 vs. 1.91 months for erlotinib; P = 0.012) and most clinically or molecularly defined subgroups, including patients with EGFR mutation-positive disease (3.71 vs. 1.91 months; P = 0.006) 39.